Iatrogenic Factors in Psychopathology
Open accessThe DOI matches its Crossref record; 83 of the 84 references it cites were found in a registry or an index; 11 of the 96 sources its claims cite were checked for support.
Abstract
The side effects and risks associated with the medical intervention are defined as iatrogenesis. Adverse drug reactions, malpractice, medical error, and negligence constitute common iatrogenic complications. Examples of important syndromes induced by medications are asthma caused by beta-adrenoceptor antagonists, pulmonary fibrosis associated with cytotoxic agents, gastric bleeding and complications with anti-inflammatory agents, torsade de pointes tachycardia with various drugs, abnormal glucose homeostasis with thiazide and corticosteroids, and osteonecrosis of the jaw with bisphosphonates. \n \nIn psychiatry, iatrogenesis has traditionally been concerned with medical complications of psychotropic drug treatment, such as tardive dyskinesia and insulin resistance with antipsychotic drugs, and cardiac and metabolic disturbances with antidepressant medications. The complications may occur due to direct toxicity, drug-drug interactions, intoxication, or withdrawal from psychotropic medications. In more recent years, attention has also been dedicated to the patient experience of negative effects of psychotherapy, including the interactions between pharmacotherapy and psychotherapy. \n \nAs it happened with medical therapy, psychiatric treatment has mainly been assessed and evaluated as to its capacity to improve psychiatric symptomatology. Side effects have been conceptualized as the unavoidable drawbacks of any form of medical therapy. Little attention has been paid to the adverse psychological and behavioral effects of psychiatric treatment on psychopathology and illness course. In view of the insufficient body of knowledge on the iatrogenic effects of psychological therapies, we will only concentrate on the effects of psychotropic drug treatment. Many of the insights that have been gained in the past 25 years have originated in this journal.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
5 Valid · 3 Not valid · 58 Not checked · 24 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Withdrawal symptoms, which may follow discontinuation of psychotropic drugs, such as benzodiazepines [36], antipsychotic medications [4,37], and antidepressant treatment [38][39][40], are also a form of behavioral toxicity.”
§ Iatrogenic Factors in Psychopathology > The Concept of Behavioral Toxicity
What the sources say
- Supportedcites [36] Fava GA, Belaise C. Discontinuing antide- pressant drugs: lesson from a failed trial and extensive clinical experience. Psychother Psy- chosom. 2018; 87(5): 257-67. source
In 'Pharmacological Strategies' our copy states that administering an antidepressant on withdrawal 'may worsen the state of behavioral toxicity which is associated with withdrawal phenomena as well as other manifestations of oppositional tolerance', directly classing withdrawal under behavioral toxicity. The opening section unifies withdrawal symptoms under the oppositional model of tolerance and adds SSRI/SNRI to the drugs inducing withdrawal 'together with BZD, barbiturates, and other psychotropic drugs', and 'First Module: Explanatory Therapy' plus 'Conclusions' apply the behavioral toxicity concept to the withdrawal/loss-of-efficacy picture. The paper therefore supports the paraphrase for antidepressant discontinuation (the part this citation is offered for) and, in its general framing, for psychotropic withdrawal. (LLM, conf=0.85)
- Not checked yetcites [4] Chouinard G, Samaha AN, Chouinard VA, Peretti CS, Kanahara N, Takase M, et al. An- tipsychotic-induced dopamine supersensitiv- ity psychosis: Pharmacology, criteria, and therapy. Psychother Psychosom. 2017; 86(4): 189-219. source
- Partly supportedcites [37] Fava GA. Rational use of antidepressant drugs. Psychother Psychosom. 2014; 83(4): 197-204. sourceExperimental — accuracy not yet measured
Our copy of Fava (2014) supports the antidepressant-specific part of the sentence: the Withdrawal Reactions section states that withdrawal symptoms follow discontinuation of AD treatment and are described for any type of AD, particularly SSRI, venlafaxine and duloxetine, and the Oppositional Model of Tolerance section attributes their appearance to oppositional processes when drug treatment ends. But the source frames these phenomena as adverse events 'subsumed under the rubric of tolerance' / manifestations of tolerance (Abstract, Introduction-Loss of AD Efficacy), and it nowhere uses or endorses the characterization 'behavioral toxicity' — searches for 'behavioral toxicity' and 'toxicity' returned only semantic neighbours, no exact phrase. The label 'a form of behavioral toxicity' is therefore the citing authors' framing, not this source's; the source also says nothing about benzodiazepine or antipsychotic withdrawal (carried by other citations). (LLM, conf=0.72)
- Not checked yetcites [38][39][40]
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Paradoxical reactions may also occur, such as increased agitation, excitement, insomnia, and talkativeness with benzodiazepines, particularly in children and the elderly [33].”
§ Iatrogenic Factors in Psychopathology > The Concept of Behavioral Toxicity
What the sources say
- Could not verifycites [33] Chouinard G, Chouinard VA. New classifica- tion of selective serotonin reuptake inhibitor withdrawal. Psychother Psychosom. 2015; 84(2): 63-71. sourceExperimental — accuracy not yet measured
Our copy of Chouinard et al. (2015) never mentions paradoxical reactions, talkativeness, or paediatric/elderly populations (searched: paradoxical reactions, talkativeness/excitement/disinhibition, children and elderly). Its only benzodiazepine content is the 'Rebound Symptoms' section, which describes withdrawal-emergent rebound insomnia, rebound anxiety and rebound panic after abrupt discontinuation of short/intermediate half-life benzodiazepines in adults — a different phenomenon from a paradoxical excitative reaction occurring during drug administration, so it neither supports nor contradicts the claim. The paper's scope is a proposed classification of SSRI/SNRI withdrawal (Tables 3-5, case series), which does not cover benzodiazepine paradoxical effects. (LLM, conf=0.70)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“If prodromal symptoms may have a pathophysiological role in affective disorders and some residual symptoms may progress to become prodromal symptoms of relapse, then reduction or disappearance of residual symptomatology may entail a more favorable long-term outcome of depression.”
§ Iatrogenic Factors in Psychopathology > The Changing Presentation of Psychiatric Disorders
What the sources say
- Supportedcites [20] Guidi J, Tomba E, Fava GA. The sequential integration of pharmacotherapy and psycho- therapy in the treatment of major depressive disorder: a meta-analysis of the sequential model and a critical review of the literature. Am J Psychiatry. 2016 Feb; 173(2): 128-37. source
The Conclusions/Evidence-Based Psychiatric Treatment opening passage states the hypothesis almost verbatim: residual symptoms' 'correlation with poor long-term outcome led to the hypothesis that residual symptoms upon recovery might progress to become prodromal symptoms of relapse and that treatment directed toward residual symptoms might yield long-term benefits.' The Sequential Treatment section reinforces it ('the preventive effects of the sequential strategy appear to be related to abatement of residual symptoms'; 'Residual symptoms are among the most powerful predictors of relapse') and the meta-analysis concludes the sequential approach 'may play a role in reducing relapse and recurrence,' i.e. a more favorable long-term outcome. Both the claim and the source keep the same hedged modality ('may'/'might'). The only clause not asserted by this paper is the antecedent about prodromal symptoms having a pathophysiological role in affective disorders, which the citing authors frame as their own conditional premise (the paper credits the prodromal-symptoms literature to Fava & Kellner 1991, reference 1); the substantive part attributed to this source — residual-to-prodromal progression and better long-term outcome from reducing residual symptomatology — is stated. (LLM, conf=0.85)
- Not checked yetcites [21] Fava GA. Do antidepressant and antianxiety drugs increase chronicity in affective disor- ders? Psychother Psychosom. 1994; 61(3-4): 125-31. source
- Not checked yetcites [22] Hall RC, Stickney SK, Gardner ER. Behavior- al toxicity of nonpsychiatric drugs. In: Hall RC, editor. Psychiatric presentations of medi- cal illness. New York: Spectrum Publications; 1980. pp. 337-49. source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
None of the sources cited for this claim have been checked yet.
In the paper
“According to the oppositional model of tolerance, continued drug treatment may recruit processes that oppose the initial acute effects of a drug.”
§ Iatrogenic Factors in Psychopathology > Pathophysiological Mechanisms of Behavioral Toxicity
What the sources say
- Not checked yetcites [41] Fava GA. Holding on: depression, sensitiza- tion by antidepressant drugs, and the prodigal experts. Psychother Psychosom. 1995; 64(2): 57-61. source
- Not checked yetcites [42] Fava GA. Can long-term treatment with anti- depressant drugs worsen the course of de- pression? J Clin Psychiatry. 2003 Feb; 64(2): 123-33. source
- Not checked yetcites [47] Feinstein AR. The pre-therapeutic classifica- tion of co-morbidity in chronic disease. J Chronic Dis. 1970 Dec; 23(7): 455-68. source
- Could not verifycites [48] Fava GA, Tossani E, Bech P, Berrocal C, Ch- ouinard G, Csillag C, et al. Emerging clinical trends and perspectives on comorbid patterns of mental disorders in research. Int J Methods Psychiatr Res. 2014 Jan; 23(S1 Suppl 1): 92- 101. sourceExperimental — accuracy not yet measured
Our copy of Fava et al. (2014) contains no passage stating or naming the 'oppositional model of tolerance'; searches for 'oppositional model of tolerance', 'oppositional process counteracts the acute effect', and 'tolerance model drug action mechanism' returned only the iatrogenic-comorbidity sections. The closest content (Abstract, 'Iatrogenic comorbidity'/'Supersensitivity') describes dopamine receptor supersensitivity following prolonged blockade and loss of therapeutic response during long-term treatment, but frames these as withdrawal/iatrogenic phenomena credited to Chouinard and Chouinard (2008) and Fava and Offidani (2011), not as a model of tolerance opposing a drug's initial acute effects. The reference list does include Fava G.A., Offidani E. (2011) 'The mechanisms of tolerance in antidepressant action', but the body text never attributes an oppositional tolerance model to it, so our copy neither supports nor contradicts the claim. (LLM, conf=0.70)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Sequential treatment was thus able to favorably affect the long-term course of depressive illness and the longitudinal development of symptoms (rollback phenomenon).”
§ Iatrogenic Factors in Psychopathology > The Changing Presentation of Psychiatric Disorders
What the sources say
- Partly supportedcites [20] Guidi J, Tomba E, Fava GA. The sequential integration of pharmacotherapy and psycho- therapy in the treatment of major depressive disorder: a meta-analysis of the sequential model and a critical review of the literature. Am J Psychiatry. 2016 Feb; 173(2): 128-37. sourceExperimental — accuracy not yet measured
The meta-analysis supports the long-term-course part: the Sequential Treatment section states the findings 'lend support to the view that the sequential administration of psychotherapy after response to acute-phase pharmacotherapy ... may play a role in reducing relapse and recurrence', with significant pooled risk ratios (0.781 overall; 0.674 after discontinuation, 0.811 with continuation) and 'feasibility and favorable long-term outcome'. However, the source frames this with explicit hedging (publication bias possibly leading to overestimation, designs that 'may have produced overly optimistic results', 'may play a role'), whereas the citing sentence asserts it as achieved ('was thus able to favorably affect'). The specific element 'the longitudinal development of symptoms (rollback phenomenon)' is not supported: our copy contains no mention of a rollback phenomenon (searched 'rollback', 'psychological costs of recovery'); it only refers to 'a longitudinal view of development of disorders that can be subsumed under the staging model' and to preventive effects 'appearing to be related to' abatement of residual symptoms, which is a hedged mechanistic remark, not a demonstrated effect on symptom trajectories. (LLM, conf=0.72)
- Not checked yetcites [21] Fava GA. Do antidepressant and antianxiety drugs increase chronicity in affective disor- ders? Psychother Psychosom. 1994; 61(3-4): 125-31. source
- Not checked yetcites [22] Hall RC, Stickney SK, Gardner ER. Behavior- al toxicity of nonpsychiatric drugs. In: Hall RC, editor. Psychiatric presentations of medi- cal illness. New York: Spectrum Publications; 1980. pp. 337-49. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
36 more claims · 3 with their cited sources checked
Create a free account to see all 90 claims and to verify the 85 references still open.
- It may state two separate claims as one. 38
- Probably not a substantial claim. 18
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hence, withdrawal symptoms that occur upon discontinuation of medications prescribed for valid medical reasons do not suggest, per se, either a substance-related (13) or an addiction disorder (6).”
From Coming Off Prescribed Psychotropic Medications: Insights from Their Use as Recreational Drugs (2020) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“New symptoms are usually the same, common to all psychotropic medications during withdrawal [12, 15, 23] (e.g., nausea, headaches, sleep disturbances) [10], but also specific and unique for a drug class (e.g., specific serotonin-related symptoms: flu-like symptoms, diarrhea, confusion) [10].”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, factors such as duration and type of treatment, prior history of exposure to AD, and pharmacological manipulations such as augmenting and switch strategies, may entail very profound implications as well.”
From May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance (2020) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“With long-term therapy, loss of treatment efficacy and some side effects (such as increased appetite and weight gain), which did not occur initially, may then appear.”
From May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance (2020) · cites this paper as [9]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Thus, similarly to rebound anxiety, the risk seems related to benzodiazepine elimination half-life and potency [20, 23] and independent form the length of treatment [1].”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [23]
Experimental — accuracy not yet measured
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Iatrogenic Factors in Psychopathology > Conclusion
“In the fifties, a sociologist, Harvey L. Smith [87], defined the psychiatrist as the marginal man of the medical profession.”
§ Iatrogenic Factors in Psychopathology > References
“86. Smith HL. Psychiatry in medicine: intra-or inter-professional relationships? Am J Sociol. 1957 Nov; 63(3): 285-9.”
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
The pre-therapeutic classification of co-morbidity in chronic disease
Feinstein, A. R. (1970) · Journal of Chronic Diseases · doi:10.1016/0021-9681(70)90054-8 · Cited by 1,544
Mechanisms of stress in the brain
McEwen, B. S., Bowles, N. P., Gray, J. D., Hill, M. N., Hunter, R. G., Karatsoreos, I. N., & Nasca, C. (2015) · Nature Neuroscience · doi:10.1038/nn.4086 · Cited by 1,386
Cuthbert, B. N. (2014) · World Psychiatry · doi:10.1002/wps.20087 · Cited by 1,377
Reed, G. M., First, M. B., Kogan, C. S., Hyman, S. E., Gureje, O., Gaebel, W., Maj, M., Stein, D. J., Maercker, A., Tyrer, P., et al. (2019) · World Psychiatry · doi:10.1002/wps.20611 · Cited by 765
X-ray structures and mechanism of the human serotonin transporter
Coleman, J. A., Green, E. M., & Gouaux, E. (2016) · Nature · doi:10.1038/nature17629 · Cited by 668
Carvalho, A. F., Sharma, M. S., Brunoni, A. R., Vieta, E., & Fava, G. A. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447034 · Cited by 650
Self-citationExploring comorbidity within mental disorders among a Danish national population
Plana-Ripoll, O., Pedersen, C. B., Holtz, Y., Benros, M. E., Dalsgaard, S., de Jonge, P., Fan, C. C., Degenhardt, L., Ganna, A., Greve, A. N., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.3658 · Cited by 584
Prevention of Recurrent Depression With Cognitive Behavioral Therapy: Preliminary Findings
Fava, G. A., Rafanelli, C., Grandi, S., Conti, S., & Belluardo, P. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.9.816 · Cited by 491
Self-citationFava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436
Self-citation
Research works printed but not linked: 4
- Ferner RE. Adverse drug reactions. Medicine (United Kingdom). 2016; 44(7): 416-21.
- Forand NR, de Rubeis RJ, Amsterdam JD. Combining medication and psychotherapy in the treatment of major mental disorders. In: Lambert MJ, editor. Bergin and Garfield's handbook of psychotherapy and behavior change. 6th ed. New York: John Wiley & Sons; 2013. pp. 735-74.
- Janicak PG, Davies JM, Preskorn SH, Ayd FJ, Marder SR, Pavuluri MN. Principles and Practice of Pharmacotherapy. 4th ed. Phila- delphia: Lippincott Williams and Wilkins; 2016. pp. 1-18.
- Robins E, Guze SB. Classification of affective disorders: the primary-secondary, the endog- enous-reactive, and the neurotic-psychotic concepts. In: Williams TA, Katz MM, Shield JA, editors. Recent Advances in the Psychobi- ology of the Depressive Illness. Washington: Government Printing Office; 1972. pp. 283- 93.
Cited by
Allostatic load and its impact on health: A systematic review
Guidi, J., Lucente, M., Sonino, N., & Fava, G. A. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000510696 · Cited by 1,266
Self-citationAcute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Cosci, F., & Chouinard, G. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506868 · Cited by 265
de Leon, J., Ruan, C.-J., Schoretsanitis, G., & De las Cuevas, C. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000507638 · Cited by 164
Evers, A. W. M., Colloca, L., Blease, C., Gaab, J., Jensen, K. B., Atlas, L. Y., Beedie, C., Benedetti, F., Bingel, U., Büchel, C., et al. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000510738 · Cited by 114
Rhee, T. G., Shim, S. R., Manning, K. J., Tennen, H. A., Kaster, T. S., d’Andrea, G., Forester, B. P., Nierenberg, A. A., McIntyre, R. S., & Steffens, D. C. (2024) · Psychotherapy and Psychosomatics · doi:10.1159/000535665 · Cited by 102
“…and/or other psychotropic medications should be carefully considered since the medications themselves can have detrimental effects on cognitive performance due in part to withdrawal symptoms and/or other iatrogenic factors (e.g., extrapyramidal side effects affecting cognitive disturbances) [71].”
BackgroundFava, G. A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320970325 · Cited by 84
Self-citationHengartner, M. P., Schulthess, L., Sorensen, A., & Framer, A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320980573 · Cited by 74
When Anxiety and Depression Coexist: The Role of Differential Diagnosis Using Clinimetric Criteria
Cosci, F., & Fava, G. A. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000517518 · Cited by 63
Self-citationUnderstanding and Managing Withdrawal Syndromes After Discontinuation of Antidepressant Drugs
Fava, G. A., & Cosci, F. (2019) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19com12794 · Cited by 69
Self-citationRafanelli, C., Gostoli, S., Buzzichelli, S., Guidi, J., Sirri, L., Gallo, P., Marzola, E., Bergerone, S., De Ferrari, G. M., Roncuzzi, R., et al. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000510006 · Cited by 60
Self-citationUnderstanding Health Attitudes and Behavior
Fava, G. A., Cosci, F., Sonino, N., & Guidi, J. (2022) · The American Journal of Medicine · doi:10.1016/j.amjmed.2022.10.019 · Cited by 72
Self-citationTrends in Antidepressant Use and Expenditure in Six Major Cities in China From 2013 to 2018
Yu, Z., Zhang, J., Zheng, Y., & Yu, L. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00551 · Cited by 67
“Considering that commercial interests have a major impact on the prescription of antidepressants, attention should be paid to the wide use of high-cost antidepressants (34, 35).”
Backgroundvan Gelderen, M. J., Nijdam, M. J., Haagen, J. F. G., & Vermetten, E. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000505977 · Cited by 59
Kathmann, N., Jacobi, T., Elsner, B., & Reuter, B. (2022) · Psychotherapy and Psychosomatics · doi:10.1159/000520454 · Cited by 58
Defining and Evaluating Overdiagnosis in Mental Health: A Meta-Research Review
Thombs, B. D., Turner, K. A., & Shrier, I. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000501647 · Cited by 57
Kim, D. D., Barr, A. M., Lu, C., Stewart, S. E., White, R. F., Honer, W. G., & Procyshyn, R. M. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000505876 · Cited by 50
Benasi, G., Fava, G. A., & Rafanelli, C. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506110 · Cited by 45
Self-citationThe Deceptive Manifestations of Treatment Resistance in Depression: A New Look at the Problem
Fava, G. A., Cosci, F., Guidi, J., & Rafanelli, C. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000507227 · Cited by 48
Self-citationWang, J., & Cosci, F. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000516031 · Cited by 47
Demoralization and Quality of Life of Patients with Parkinson Disease
Zhu, B., Kohn, R., Patel, A., Koo, B. B., Louis, E. D., & de Figueiredo, J. M. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000514270 · Cited by 47
Fava, G. A. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000520251 · Cited by 46
Self-citationThe Management of Obesity in People with Severe Mental Illness: An Unresolved Conundrum
Holt, R. I. G. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000503835 · Cited by 42
The emerging role of euthymia in psychotherapy research and practice
Guidi, J., & Fava, G. A. (2020) · Clinical Psychology Review · doi:10.1016/j.cpr.2020.101941 · Cited by 40
Self-citationClinical Interviewing: An Essential but Neglected Method of Medicine
Fava, G. A., Sonino, N., Aron, D. C., Balon, R., Montiel, C. B., Cao, J., Concato, J., Eőry, A., Horwitz, R. I., Rafanelli, C., et al. (2024) · Psychotherapy and Psychosomatics · doi:10.1159/000536490 · Cited by 38
Self-citationCosci, F., Mansueto, G., & Fava, G. A. (2020) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2020.1779308 · Cited by 29
Self-citationPsychotherapy in recurrent depression: efficacy, pitfalls, and recommendations
Cosci, F., Guidi, J., Mansueto, G., & Fava, G. A. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1804870 · Cited by 31
Self-citationConceptual and Clinical Innovations of Well-being Therapy
Guidi, J., & Fava, G. A. (2021) · International Journal of Cognitive Therapy · doi:10.1007/s41811-021-00101-1 · Cited by 30
“Treatment resistance thus calls for switching and augmentation which may trigger a “cascade iatrogenesis” (Fava and Rafanelli 2019) instead of reconsideration of the process in treatment selection.”
BackgroundSelf-citationCosta, M. D. A., Gonçalves, F. G., Tatton-Ramos, T., Fonseca, N. K. D. O. D., Schwinn, J. K., Alves, S. G., Salum, G. A., & Manfro, G. G. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000511880 · Cited by 26
Charlson, M. E., & Wells, M. T. (2022) · Psychotherapy and Psychosomatics · doi:10.1159/000521952 · Cited by 25
Patients as Health Producers: The Psychosomatic Foundation of Lifestyle Medicine
Fava, G. A. (2023) · Psychotherapy and Psychosomatics · doi:10.1159/000529953 · Cited by 28
Self-citationDifficult-To-Treat Depression. Scoping Review.
Paganin, W., Signorini, S. G., & Sciarretta, A. (2023) · PubMed Central · doi:10.36131/cnfioritieditore20230302 · Cited by 28
“…& New Zealand Journal of Psychiatry Australia 7 Demyttenaere e Van Duppen, 2019 Review Article International Journal of Neuropsychopharmacology UK 8 Fava & Rafanelli, 2019 Editorial Psychotherapy and Psychosomatics Switzerland 9 Fava et al., 2020 Editorial Psychotherapy and Psychosomatics…”
BackgroundPalagini, L., Geoffroy, P. A., & Riemann, D. W. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666211214164907 · Cited by 25
More Treatment, but Not Less Anxiety and Mood Disorders: Why? Seven Hypotheses and Their Evaluation
Ormel, J., & Emmelkamp, P. M. G. (2023) · Psychotherapy and Psychosomatics · doi:10.1159/000528544 · Cited by 23
Alternative Diagnostic Models of the Psychotic Disorders: Evidence-Based Choices
Cohen, B. M., Öngür, D., & Babb, S. M. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000517027 · Cited by 19
Prescribing Pharmacotherapy for Major Depressive Disorder: How Does a Clinician Decide?
Cosci, F., & Fava, G. A. (2021) · Biomedicine Hub · doi:10.1159/000519656 · Cited by 19
Self-citationComing Off Prescribed Psychotropic Medications: Insights from Their Use as Recreational Drugs
Schifano, F. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000507897 · Cited by 18
Svensson, M., Nilsson, T., Perrin, S., Johansson, H., Viborg, G., Falkenström, F., & Sandell, R. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000511469 · Cited by 17
Kimura, H., Kanahara, N., & Iyo, M. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113126 · Cited by 17
Schmid, C., Hansen, K., Kröner‐Borowik, T., & Steil, R. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000512757 · Cited by 15
The Decline of Pluralism in Medicine: Dissent Is Welcome
Fava, G. A. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000505085 · Cited by 15
Self-citationCohen, D., & Recalt, A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320964097 · Cited by 15
Cosci, F. (2023) · Psychotherapy and Psychosomatics · doi:10.1159/000535262 · Cited by 12
“Patients may discover this problematic implication of selective serotonin reuptake inhibitor use when they reduce or discontinue the drug that is too late, being already in the track of iatrogenesis [34].”
BackgroundManagement of Depression in Medical Patients: The Role of Clinical Evaluation
Fava, G. A., & Guidi, J. (2023) · Psychotherapy and Psychosomatics · doi:10.1159/000533954 · Cited by 12
“In both cases of symptomatic affective disorders (medications and illnesses), risk factors are history of depression and psychosocial stressors [2, 13, 14, 20, 21].”
BackgroundInfluentialSelf-citationThe Role of Clinical Judgment in Psychiatry
Fava, G. A., & Guidi, J. (2025) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.70035 · Cited by 11
“The concept of vulnerability is not limited to side effects, but it is extended to iatrogenic factors [31, 32].”
InfluentialSelf-citationPatacchini, A., & Cosci, F. (2021) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-200074 · Cited by 12
“Sexual dysfunction is known as a common side effect of antidepressant treatment [1,2].”
Differential impact of resilience on demoralization and depression in Parkinson disease
de Figueiredo, J. M., Zhu, B., Patel, A., Kohn, R., Koo, B. B., & Louis, E. D. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1207019 · Cited by 11
“Iatrogenic effects of medications used to treat PD might be unmeasured confounders (55).”
BackgroundDisorder or distress? The hermeneutical injustices of overdiagnosis within psychiatry
Nielsen, T. H. (2025) · Synthese · doi:10.1007/s11229-024-04902-7 · Cited by 15
“For instance, treatment within psychiatry often involves psychotropic solutions, many of which carry serious side effects and can create dependencies among many other harmful iatrogenic effects (Fava & Rafanelli, 2019).”
Elsaeßer, M., Feige, B., Kriston, L., Schumacher, L., Peifer, J., Hautzinger, M., Härter, M. C., & Schramm, E. (2023) · Psychotherapy and Psychosomatics · doi:10.1159/000535005 · Cited by 10
“This might be particularly useful to manage long-term consequences of prolonged pharmacological treatment [35, 36, 41] and to advance the ongoing debate about treatment-resistance and dif fi cult-to-treat depression [42 – 45].”
BackgroundWatchful waiting for depression using depathologization, advice and shared decision making
Kostic, M. V., Milojevic, T., Buzejić, J., Stojaković, M. S., Maslak, J., Ilić, M., Jakovljevic, A., Munjiza, A., Podgorac, A., Dabetic, M., et al. (2024) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2024.100753 · Cited by 14
Barbalat, G., Reddy, G., & Franck, N. (2023) · Globalization and Health · doi:10.1186/s12992-023-00980-3 · Cited by 11
“If increased psychotropic prescriptions are a key characteristic of globalized countries, then mental and substance use disorders that are mostly treated pharmacologically may be associated with other iatrogenic disorders, such as obesity, diabetes, or sexual dysfunctions [74].”
BackgroundMeasuring clinical findings: the value of clinimetrics
Fava, G. A., Sonino, N., & Guidi, J. (2025) · Postgraduate Medical Journal · doi:10.1093/postmj/qgaf082 · Cited by 10
Self-citationRevisitando Whitaker: psicofármacos e cuidado em Saúde Mental na Atenção Primária à Saúde
Secco, A. C., & Tesser, C. D. (2023) · Saúde em Debate · doi:10.1590/0103-1104202313916 · Cited by 12
Schaich, A., Outzen, J., Assmann, N., Gebauer, C., Jauch‐Chara, K., Alvarez‐Fischer, D., Hüppe, M., Wells, A., Schweiger, U., Klein, J. P., et al. (2022) · Psychotherapy and Psychosomatics · doi:10.1159/000527482 · Cited by 8
Parsing the heterogeneity of depression: a data-driven subgroup derived from cognitive function
Xu, C., Tao, Y., Lin, Y., Zhu, J., Li, Z., Li, J., Wang, M., Huang, T., & Shi, C. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1537331 · Cited by 8
Cosci, F., Chouinard, V., & Chouinard, G. (2023) · Psychotherapy and Psychosomatics · doi:10.1159/000530692 · Cited by 7
Peer support’s role in helping individuals withdraw from psychiatric medications
Maviglia, M. A., Hume, D., & Cooeyate, N. J. (2023) · Journal of Psychology & Clinical Psychiatry · doi:10.15406/jpcpy.2023.14.00746 · Cited by 5
Cantú, A. (2023) · Journal of Humanistic Psychology · doi:10.1177/00221678231167612 · Cited by 4
“The DSM and biomedical model have been shown to contribute to stigma (Read & Magliano, 2019) and iatrogenic harm (Boisvert & Faust, 2002; Fava & Rafanelli, 2019).”
Depression screening in pregnancy and postpartum: Just do something?
Thombs, B. D., Rice, D. B., Markham, S., & Ziegelstein, R. C. (2023) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2023.02.005 · Cited by 4
The Clinical Meaning of Withdrawal with Antidepressant Drugs
Fava, G. A. (2024) · Psychotherapy and Psychosomatics · doi:10.1159/000540033 · Cited by 4
“Another characteristic of my assessment was my attention to potential iatrogenic factors that are often neglected by physicians in all specialties [17].”
Self-citationTreatment-resistant depression: time to rethink current definitions and clinical practice
Paganin, W. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1733678 · Cited by 3
“The TRD framework may lead to what Fava and Rafanelli (20) describe as “ cascade iatrogenesis ” .”
Nature and Nurturance Across the Ages: Modest Means for Modern Times
Moller, H. J., Saynor, L., Chignell, M., & Waterworth, J. A. (2020) · Lecture notes of the Institute for Computer Sciences, Social Informatics and Telecommunications Engineering · doi:10.1007/978-3-030-53294-9_39 · Cited by 3
An Editor’s Journey Ends, but the Journal’s Mission Continues
Fava, G. A. (2022) · Psychotherapy and Psychosomatics · doi:10.1159/000524654 · Cited by 5
Self-citationBoyle, A., Abdulla, S., Odrowąż‐Coates, A., Tah, J. K., Kiss, J., Grung, R. M., Ahlström, M., & Marsh, L. (2023) · Society Register · doi:10.14746/sr.2023.7.2.03 · Cited by 2
Lebrat, M., Mégard, R., Blandin, A.-C., Franck, N., & Zimmer, L. (2024) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s481398 · Cited by 2
“11 The authors discussed key concepts such as “behavioral toxicity”, “iatro-genic comorbidity” and “cascade iatrogenesis” involved in current classification systems, which fail to consider the iatrogenic burden of psychopathology related to behavioral toxicity (defined as pharmacological actions of…”
Escitalopram-Associated Tongue Hypoesthesia
Chauhan, A., & Praharaj, S. K. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001368 · Cited by 2
Fava, G. A. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000511544 · Cited by 2
Self-citationdo Amaral, L. H., & Marzal, J. (2023) · The International Library of Bioethics · doi:10.1007/978-3-031-22891-9_2 · Cited by 1
Ormel, J., & Emmelkamp, P. M. G. (2025) · Verhaltenstherapie · doi:10.1159/000542334 · Cited by 1
Correlates of Loneliness in Parkinson Disease During the COVID-19 Pandemic: A Longitudinal Study
de Figueiredo, J. M., Kohn, R., Patel, A., Parsons, E., Louis, E. D., & Koo, B. B. (2025) · Behavioral Sciences · doi:10.3390/bs15091233 · Cited by 1
“Potential unmeasured confounders, such as iatrogenic effects of medications used to treat PD, may have influenced the results (Fava & Rafanelli, 2019).”
Iatrogenic Psychopathology in Chronic Pain
Streltzer, J. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000502153 · Cited by 1
Developing an App to Screen for Dual Disorders: A Tool for Improving Treatment Services in Mexico
Marín-Navarrete, R., Torrens, M., Toledo-Fernández, A., Mestre-Pintó, J. I., Sánchez-Domínguez, R., Pérez-López, A., Saracco-Álvarez, R. A., León, E. Á. M.-D., & Szerman, N. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.697598 · Cited by 1
“In this respect, we inferred that the peer-to-peer care model with untrained staff and a lack of standardized procedures for treating patients with DDs increases the risk of iatrogenic harm, malpractice and negligence (26–28).”
BackgroundInnovation in psychopharmacology
Serretti, A. (2023) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000493 · Cited by 1
The Impoverishment of Psychiatric Knowledge
Aftab, A., & Fava, G. A. (2024) · Oxford University Press eBooks · doi:10.1093/med/9780192870322.003.0005
Self-citationPandiyammal, V., & Raja, U. K. (2020) · Malaya Journal of Matematik · doi:10.26637/mjm0804/0084
Urgences psychiatriques en fonction des pathologies psychiatriques
Baudry, T., & Peretti, C.-S. (2021) · Elsevier eBooks · doi:10.1016/b978-2-294-76698-5.00004-2
Die Ingenieurstudentin und der Tunnel
Fava, G. A. (2022) · Ärztliche Psychotherapie · doi:10.21706/aep-17-3-226
Self-citationHummelvoll, J. K., & Eriksson, B. G. (2022) · Springer eBooks · doi:10.1007/978-3-031-05536-2_10
Intrusive violent images as a side effect of clozapine usage
Martins, S. N., Romano, C. A., Martins, P., Felgueiras, J., & Ribeiro, B. (2023) · Psychiatry Research Case Reports · doi:10.1016/j.psycr.2023.100155
Well-Being Therapy for Depression
Romanazzo, S., & Cosci, F. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-981-97-4402-2_14
Le contexte de l’arrêt guidé des antidépresseurs
Fava, G. A., & Peretti, C.-S. (2024) · Elsevier eBooks · doi:10.1016/b978-2-294-77932-9.00006-6
Self-citationLes manifestations cliniques associées à la toxicité comportementale
Fava, G. A., & Peretti, C.-S. (2024) · Elsevier eBooks · doi:10.1016/b978-2-294-77932-9.00003-0
Self-citationUne psychiatrie différente est possible
Fava, G. A., & Peretti, C.-S. (2024) · Elsevier eBooks · doi:10.1016/b978-2-294-77932-9.00013-3
Self-citationDie Rolle des klinischen Urteilsvermögens in der Psychiatrie
Fava, G. A., & Guidi, J. (2026) · Ärztliche Psychotherapie · doi:10.21706/aep-21-3-190
Self-citation
Metadata
- Authors
- Fava, G. A., & Rafanelli, C.
- Affiliations
- University at Buffalo, State University of New York (US)
- University of Bologna (IT)
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2019
- Volume
- 88
- Issue
- 3
- Pages
- 129-140
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W2946703117
- Cited by
- 82
- References
- 84
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 10 · 2023: 16 · 2022: 7 · 2021: 14 · 2020: 22 · 2019: 5
- FWCI
- 9.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Funders
- Compagnia di San Paolo
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- iatrogenesis, psychotropic drugs, adverse drug reactions, tardive dyskinesia, antipsychotic adverse effects, antidepressant side effects, drug-drug interactions, drug withdrawal, psychopathology
- MeSH terms
- Humans, Iatrogenic Disease, Psychopathology, Psychotropic Drugs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.